Fanli Biotechnology (Ningbo) Co., Ltd.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Fanli Biotechnology (Ningbo) Co., Ltd. - overview
Established
2023
Location
Ningbo, Zhejiang, China
Primary Industry
Biotechnology
About
Based in Ningbo, China and founded in 2023, Fanli Biotechnology (Ningbo) Co. , Ltd. is a biotechnology research and development company. In January 2026, Fanli Biotechnology (Ningbo) Co.
, Ltd. raised a Series A+ funding from Xiamen C&D Emerging Industry Equity Investment and Hongfeng Venture. The company primarily engages in medical research and experimental development to meet the needs of clinical trials and related activities. The company's revenue is generated by providing medical research and experimental development.
Current Investors
Huagai Capital, Loyal Valley Capital, Guangxi Tencent Venture Capital
Primary Industry
Biotechnology
Sub Industries
Biotechnology
Company Stage
Series A
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.